Insmed Incorporated (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 31,805 shares of the company's stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $70.18, for a total transaction of $2,232,074.90. Following the sale, the chief executive officer now directly owns 379,534 shares in the company, valued at $26,635,696.12. This represents a 7.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.
William Lewis also recently made the following trade(s):
- On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The stock was sold at an average price of $63.36, for a total value of $188,686.08.
- On Tuesday, January 7th, William Lewis sold 8,218 shares of Insmed stock. The shares were sold at an average price of $66.02, for a total value of $542,552.36.
- On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $69.84, for a total value of $1,309,500.00.
- On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.91, for a total value of $1,310,812.50.
Insmed Trading Up 3.6 %
NASDAQ INSM traded up $2.55 during trading on Thursday, reaching $72.75. 2,264,024 shares of the stock traded hands, compared to its average volume of 2,139,833. The stock's 50-day moving average price is $71.18 and its 200 day moving average price is $72.47. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The firm has a market cap of $13.01 billion, a price-to-earnings ratio of -13.11 and a beta of 1.12. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $80.53.
Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts' consensus estimates of ($1.19) by ($0.08). The company had revenue of $93.40 million for the quarter, compared to analyst estimates of $93.36 million. The firm's quarterly revenue was up 18.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.10) EPS. Analysts predict that Insmed Incorporated will post -5.44 EPS for the current year.
Analyst Ratings Changes
A number of equities analysts have weighed in on the stock. JPMorgan Chase & Co. boosted their target price on shares of Insmed from $74.00 to $83.00 and gave the stock an "overweight" rating in a research note on Friday, November 22nd. Truist Financial reaffirmed a "buy" rating and set a $105.00 price objective (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. Bank of America lifted their target price on Insmed from $84.00 to $86.00 and gave the company a "buy" rating in a research note on Wednesday, October 9th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $90.00 price target on shares of Insmed in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to MarketBeat, Insmed has an average rating of "Moderate Buy" and a consensus target price of $83.67.
Get Our Latest Stock Report on Insmed
Institutional Investors Weigh In On Insmed
A number of hedge funds have recently modified their holdings of the business. Darwin Global Management Ltd. bought a new stake in Insmed during the 2nd quarter worth approximately $237,076,000. Vestal Point Capital LP increased its position in shares of Insmed by 113.3% during the third quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company's stock worth $116,800,000 after acquiring an additional 850,000 shares in the last quarter. Clearbridge Investments LLC raised its holdings in shares of Insmed by 76.8% during the second quarter. Clearbridge Investments LLC now owns 1,644,948 shares of the biopharmaceutical company's stock worth $110,212,000 after acquiring an additional 714,539 shares during the period. Farallon Capital Management LLC bought a new stake in Insmed in the 2nd quarter valued at $38,056,000. Finally, Fred Alger Management LLC acquired a new position in Insmed in the 2nd quarter worth $33,404,000.
About Insmed
(
Get Free Report)
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Insmed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insmed wasn't on the list.
While Insmed currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
